NCT03620981View on ClinicalTrials.gov

Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

410

Participants

Timeline

Start Date

August 20, 2018

Primary Completion Date

April 21, 2023

Study Completion Date

May 15, 2023

Conditions
Agitation Associated With Dementia of the Alzheimer's Type
Interventions
DRUG

Brexpiprazole

Drug: 1 tablet /day Once daily for 10 weeks

DRUG

Placebo

Placebo: 1 tablet /day Once daily for 10 weeks

Trial Locations (1)

Unknown

Jisenkai Nanko Psychiatric Institute, Shirakawa

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

NCT03620981 - Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type | Biotech Hunter | Biotech Hunter